Systematic Biopsy Enhances Detection in Biparametric MRI-Guided Prostate Cancer Diagnosis

Overview

This multi-center study validates the complementary role of systematic biopsy (SBx) alongside biparametric MRI-targeted biopsy (TBx) in men suspected of prostate cancer. Despite the advantages of TBx, SBx detects a significant proportion of clinically significant prostate cancers (csPCa) that TBx alone may miss.

Background

Magnetic Resonance Imaging (MRI) has become integral in prostate cancer diagnosis, with biparametric MRI offering a faster, contrast-free alternative. MRI-targeted biopsy (TBx) has shown superiority over systematic biopsy (SBx) in detecting prostate cancer, prompting investigation into whether SBx can be omitted to reduce patient morbidity and pathology workload. However, omitting SBx risks missing clinically significant cancers, as some lesions are not visible or are mis-targeted during TBx. This study aimed to develop and validate a nomogram incorporating MRI volumetric and clinical data to guide when SBx should be added to TBx.

Data Highlights

Key Findings

• Omitting systematic biopsy would miss approximately 16% of clinically significant prostate cancers in biopsy-naive patients.
• Three main reasons for TBx failure include lesion misdiagnosis, presence of MRI-invisible csPCa, and targeting errors.
• Smaller lesions in larger prostates are more likely to be missed by TBx alone.
• The study developed and externally validated a nomogram based on MRI volumetrics and clinical data to identify when SBx should be added.
• All patients underwent biparametric MRI with standardized protocols and centralized reporting to ensure data integrity.
• Systematic biopsy remains important to complement TBx to avoid missing significant cancers despite increased workload and morbidity.

Clinical Implications

Clinicians should consider performing systematic biopsy in addition to biparametric MRI-targeted biopsy, especially in patients with smaller lesions or larger prostate volumes, to reduce the risk of missing clinically significant prostate cancer. The validated nomogram may assist in individualized decision-making to balance diagnostic accuracy with procedural risks and resource use.

Conclusion

Systematic biopsy continues to play a critical role alongside biparametric MRI-targeted biopsy in detecting clinically significant prostate cancer. Incorporating MRI volumetric parameters and clinical data can guide biopsy strategies to optimize cancer detection while minimizing unnecessary sampling.

References

1. Jambor et al. 2020 -- The Enhanced Role of Systematic Biopsy in Men Suspected of Prostate Cancer Undergoing Biparametric MRI-Guided Biopsy